EC approves first allogeneic T cell therapy for rare post-transplant complication

Paul Schloesser

Associate Editor

The European Commission signed off on the continent’s first allogeneic T cell therapy Monday. And for its maker Atara Biotherapeutics, the approval marks the biotech’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EC approves first allogeneic T cell therapy for rare post-transplant complication

Paul Schloesser

Associate Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

EC ap­proves first al­lo­gene­ic T cell ther­a­py for rare post-trans­plant com­pli­ca­tion

Associate Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

EC approves first allogeneic T cell therapy for rare post-transplant complication